Pharmaceutical Technology3d
Risk adjusted net present value: What is the current valuation of AstraZeneca’s Eneboparatide?
Eneboparatide is a recombinant peptide commercialized by AstraZeneca, with a leading Phase III program in Hypoparathyroidism.
Too Old to Operate5d
Higher and Increasing Disordered Eating Levels Linked to Cardiometabolic Risks
The following is a summary of “Disordered Eating Profiles in Adolescence to Early Adulthood and Future Cardiometabolic Health ...
Too Old to Operate5d
Virtual 3D Models Enhance Parathyroid Tumor Surgery and Patient Satisfaction
The following is a summary of “Development of patient-specific 3D anatomical models in minimally invasive parathyroidectomy,” ...